Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.73M Sell
4,100
-2,000
-33% -$797K 0.82% 23
2026
Q2
$2.21M Sell
6,100
-200
-3% -$68.5K 1.03% 22
2026
Q1
$2.22M Sell
6,300
-1,495
-19% -$533K 1.17% 22
2025
Q4
$2.55M Sell
7,795
-5,610
-42% -$1.78M 1.35% 21
2025
Q3
$3.78M Sell
13,405
-155
-1% -$45K 2.08% 14
2025
Q2
$3.79M Sell
13,560
-340
-2% -$96.3K 2.09% 14
2025
Q1
$4.33M Hold
13,900
– – 2.59% 14
2024
Q4
$3.62M Sell
13,900
-2,763
-17% -$820K 2.48% 14
2024
Q3
$5.37M Buy
16,663
+400
+2% +$131K 3.63% 12
2024
Q2
$5.08M Buy
16,263
+753
+5% +$221K 3.64% 9
2024
Q1
$4.41M Buy
15,510
+4,005
+35% +$1.17M 3.34% 13
2023
Q4
$3.31M Buy
11,505
+3,205
+39% +$873K 2.7% 15
2023
Q3
$2.23M Hold
8,300
– – 1.89% 18
2023
Q2
$1.84M Hold
8,300
– – 1.52% 22
2023
Q1
$2.01M Sell
8,300
-1,100
-12% -$270K 1.79% 20
2022
Q4
$2.47M Hold
9,400
– – 2.32% 18
2022
Q3
$2.12M Hold
9,400
– – 2.11% 18
2022
Q2
$2.29M Hold
9,400
– – 2.17% 18
2022
Q1
$2.27M Hold
9,400
– – 1.85% 20
2021
Q4
$2.12M Buy
+9,400
New +$1.98M 1.71% 18

Other funds holding AMGN

Gouws Capital's AMGN Position: Q3 2026 in Review

Gouws Capital reduced its Amgen (AMGN) stake by 33% in Q3 2026, selling an estimated $797K and leaving 4,100 shares worth $1.73M. The position accounts for 0.82% of the portfolio, ranked #23.

Gouws Capital first reported a position in AMGN in Q4 2021 and has held it in 20 quarters since. The position peaked at $5.37M in Q3 2024. 3,119 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Gouws Capital held 4,100 shares of Amgen worth $1.73M as of Q3 2026.
  • Gouws Capital sold 2,000 Amgen shares in Q3 2026, an estimated $797K.
  • Amgen made up 0.82% of Gouws Capital's portfolio in Q3 2026, its #23 holding.
  • Gouws Capital first reported a position in Amgen in Q4 2021 and has held it in 20 quarters since.
  • Gouws Capital's Amgen position peaked at $5.37M in Q3 2024.
  • 3,119 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Gouws Capital's 13F filing for Q3 2026, filed 9 Oct 2026.